‘More mortality, more illness’: Global health community braces for impact of U.S. election
Scientists worry Trump will leave WHO and make deep cuts in programs that aim to control diseases worldwide
Related Articles
This elephant learned to use a hose as a shower. Then her rival sought revenge
Behaviors reveal sophisticated tool use—and possible “pranking”—among pachyderms
Sequence modeling and design from molecular to genome scale with Evo
The genome is a sequence that encodes the DNA, RNA, and proteins that orchestrate an organism’s function. We present Evo, a long-context genomic foundation model…
Digital determinants of health important with growing technology usage
Digital determinants of health could include factors like ease of use, interactivity, digital literacy, broadband access and more.
OpenAI isn’t built for health care. So why is its tech already in hospitals, pharma, and cancer care?
OpenAI isn’t built for health care but it’s already inking deals with health care companies.
Babylon founder Ali Parsa launches AI assistant for doctors as new startup emerges from stealth
Confirming earlier Sifted reporting, Quadrivia has secured pre-seed investment from Swedish VC Norrsken
Fostering health IT innovation through academic-industrial
At the helm of Taiwan’s national smart health project, the National Science and Technology Council facilitates partnerships between university hospitals and the ICT industry. Andrea…
High-temperature carbon dioxide capture in a porous material with terminal zinc hydride sites
Carbon capture can mitigate point-source carbon dioxide (CO2) emissions, but hurdles remain that impede the widespread adoption of amine-based technologies. Capturing CO2 at temperatures closer…
Billions of dollars have been invested in healthcare AI. But are we spending in the right places?
The presence of AI in healthcare is rapidly growing – but resource allocation will determine whether the technology has a positive impact.
How much power do Trump and Kennedy have to reshape health agencies?
Georgetown University’s Lawrence Gostin weighs in on what the new administration can—and can’t—do to at FDA, CDC, and NIH
A breakthrough cancer immunotherapy is now taking aim at autoimmune disease
CAR-T therapy is generating excitement for lupus, scleroderma, and other conditions as clinical trials expand
